Merck's Clark elected board chairman of PhRMA

Share this article:
PhRMA members elected Merck's Dick Clark to serve as this year's chairman of the board, with AstraZeneca's David Brennan next in line as chairman-elect and Pfizer's Jeff Kindler being named board treasurer.
Clark, who took over as CEO of Merck in 2005 and is widely credited with turning the company around, succeeds Amgen's Kevin Sharer in the role, which he'll hold for one year. PhRMA president and CEO Billy Tauzin saluted Sharer for providing “steady and motivating guidance to our industry during his tenure – a time when challenges are significant but our companies' commitment to research and development remains strong.”
Joining the group's board as full members were Takeda North America president Mark Booth, Sigma Tau COO Greg Lapointe and Ovation president and CEO Jeff Aronin. Other recent additions include Wyeth president/CEO Bernard Poussot, Lilly president and COO John Lechleiter and GSK president, US pharma Chris Viebacher.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.